Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
Julie is a dedicated resource for summer associates and associates who want to sharpen their legal writing skills. She works one-on-one with lawyers and teaches workshops that address common writing challenges. In Chambers Associate, our associates called Julie "an invaluable asset to the firm."
Women in Law Empowerment Forum awarded Schiff Hardin its 2015 Gold Standard in Recognition of Integration of Women in the Firm for the 3rd straight year. Schiff Hardin was one of only eight firms in the nation to earn a perfect score.
Imron T. Aly is a trial lawyer who serves as lead counsel for clients on dozens of matters, and has first-chaired more than 10 trials. Imron is co-leader of Schiff Hardin’s Intellectual Property Group and co-chair of the firm's Hatch-Waxman and Biosimilars patent litigation team. His practice is focused on patent infringement litigation. He has litigated and tried patent infringement and other IP matters related to pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods, and financial trading systems. Clients and leading industry publications describe Imron as a prepared courtroom advocate whose “tenacity sets him apart,” who “stands out for his pure advocacy skills,” and “is an untiring advocate for his clients’ cause.”
Prior to joining Schiff Hardin, Imron was an intellectual property partner in the Chicago office of an international law firm.
Ninety-six Schiff Hardin lawyers have been named to the 2018 Leading Lawyers lists for Illinois and Michigan.
Forty Schiff Hardin attorneys have been recognized on the 2018 Illinois Super Lawyers and Rising Stars lists.
Schiff Hardin LLP is pleased to announce that Imron Aly, partner and Intellectual Property Group co-leader, has been recognized as a Most Influential Minority Lawyer in Chicago by Crain’s Chicago Business.
Schiff Hardin LLP has been ranked as a “Recommended Firm” in Illinois in the 2018 edition of Benchmark Litigation, an annual guide to the leading litigation firms and attorneys in the United States.
IPRs have become a common, attractive tool for patent challengers because of their more favorable standard of review and one-year deadline to final written decision.
Earlier this week, the U.S. Supreme Court unanimously held, in its first case interpreting the Biologics Price Competition and Innovation Act of 2009, Sandoz Inc. v. Amgen Inc.
Schiff Hardin Intellectual Property Practice Group Co-Leader Imron Aly has been recognized as a leading patent litigator in Illinois in the 2017 IAM Patent 1000 guide, based on outstanding feedback from peers and clients.
Schiff Hardin LLP has been recognized as one of the top law firms defending Abbreviated New Drug Application (ANDA) litigation in the 2017 Hatch-Waxman/ANDA Litigation Report compiled by legal data analytics firm Lex Machina.
World Intellectual Property Review
Imron has represented indigent clients in trademark and copyright, contract dispute, landlord-tenant, prisoner rights, and elder abuse matters.
Law Bulletin’s Illinois Leading Lawyers Network
Crain’s Chicago Business
Legal Media Group
Managing Intellectual Property
IAM Patent 1000
Law Bulletin's Illinois Leading Lawyers Network
BTI Power Ranking
Managing Intellectual Property Magazine
Globe Business Media Group's The World’s Leading Patent Practitioners (2014, 2015)
Chambers USA: America’s Leading Lawyers for Business (2014)
Euromoney's Benchmark Litigation (2013, 2014)
Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and... Continue Reading
Schiff Hardin’s pharma and life sciences patent litigation team, led by partner Imron T. Aly, recently secured a preliminary injunction in federal court. Representing generic drug manufacturer Fresenius Kabi USA, LLC, our team convinced the judge to bar our client’s competitor from launching a generic version of levothyroxine, our client’s patented treatment formulation.